ARS Pharmaceuticals (SPRY) Other Non-Current Liabilities (2021 - 2026)
ARS Pharmaceuticals' (SPRY) quarterly Other Non-Current Liabilities came in at $4.5 million in Q1 2026, down 2.76% quarter-over-quarter from $4.6 million in Q4 2025.
ARS Pharmaceuticals (SPRY) Other Non-Current Liabilities (2021 - 2026) Analysis & Trends
ARS Pharmaceuticals has disclosed Other Non-Current Liabilities across 3 years of filings, most recently posting $4.5 million for Q1 2026.
- Other Non-Current Liabilities for Q1 2026 came in at $4.5 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $4.5 million (changed N/A YoY), and the FY2025 annual result was $4.6 million, changed N/A from the prior year.
- Other Non-Current Liabilities came in at $4.5 million for Q1 2026 at ARS Pharmaceuticals, down from $4.6 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $4.6 million in Q4 2025 to a low of $1.4 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | ARS Pharmaceuticals | 954.24 Mn | 753.27 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.48 Mn |
| Dec 31, 2025 | 4.61 Mn |
| Sep 30, 2025 | 3.78 Mn |
| Jun 30, 2025 | 1.42 Mn |
| Dec 31, 2021 | 83,000.00 |